Next Article in Journal
Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder
Previous Article in Journal
Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease
Previous Article in Special Issue
Combinations of drugs in the Treatment of Obesity
Pharmaceuticals 2010, 3(12), 3494-3521; doi:10.3390/ph3123494

Obesity Drug Update: The Lost Decade?

 and *
Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI 48201, USA
* Author to whom correspondence should be addressed.
Received: 5 October 2010 / Revised: 17 November 2010 / Accepted: 23 November 2010 / Published: 24 November 2010
(This article belongs to the Special Issue Anti-Obesity Drugs)
View Full-Text   |   Download PDF [294 KB, uploaded 24 November 2010]   |   Browse Figure


The growing worldwide obesity epidemic and obesity-related disorders present a huge unmet medical need for safe and effective anti-obesity medications. The discovery of leptin in 1994 was rapidly succeeded by a wave of related discoveries leading to the elaboration of a hypothalamic melanocortinergic neuronal circuit regulated by leptin and other central and peripheral signaling molecules to control energy homeostasis. The identification of specific neuronal subtypes along with their unique connections and expression products generated a rich target menu for anti-obesity drug discovery programs. Over the course of the last decade, several new chemical entities aimed at these targets have reached various stages or successfully completed the drug discovery/regulatory process only to be dropped or taken off the market. There are now in fact fewer options for anti-obesity drug therapies in late 2010 than were available in 2000. The challenge to discover safe and effective anti-obesity drugs is alive and well.
Keywords: obesity; anti-obesity drug targets; anti-obesity drugs; hypothalamus obesity; anti-obesity drug targets; anti-obesity drugs; hypothalamus
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Yao, F.; MacKenzie, R.G. Obesity Drug Update: The Lost Decade? Pharmaceuticals 2010, 3, 3494-3521.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert